Fig. 1From: Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritisDose-normalized geometric mean plasma concentration–time profile of namilumab (error bars show ± 1 SD). SD standard deviationBack to article page